Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 19 Neoplasm Metastasis 6 Brain Neoplasms 4 Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Triple Negative Breast Neoplasms 2 Lung Neoplasms 2 Uterine Cervical Neoplasms 1 Stomach Neoplasms 1 Salivary Gland Neoplasms 1 Rare Tumour 1 Prostatic Neoplasms 1 Pathologic Complete Response 1 Ovarian Neoplasms 1 Neuroma, Acoustic 1 Neurofibromatosis 2 1 Meningioma 1 Malignant Female Reproductive System Neoplasm 1 Hemangiosarcoma 1 HER2-positive Breast Cancer 1 HER2 Positive Breast Carcinoma 1 Glioblastoma 1 Fallopian Tube Neoplasms 1 Ependymoma 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Pancreatic Ductal 1 Carcinoma, Lobular 1 Carcinoma 1

Interventions

Fulvestrant 9 olaparib 4 Capecitabine 4 pyrotinib 3 Injections 3 Docetaxel 3 trastuzumab deruxtecan 2 toripalimab 2 Vinorelbine 2 Trastuzumab 2 Letrozole 2 Goserelin 2 Alpelisib 2 vandetanib 1 talazoparib 1 sacituzumab govitecan 1 pembrolizumab 1 neratinib 1 liposomal doxorubicin 1 exemestane 1 eribulin 1 dalpiciclib 1 ceralasertib 1 cediranib 1 capivasertib 1 abemaciclib 1 Tablets 1 Paclitaxel 1 Moxifloxacin 1 Lead 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Advanced Breast Cancer × neratinib × Clear all

NCT03182634 2019-01-22

plasmaMATCH

Institute of Cancer Research, United Kingdom

Phase 2 Unknown

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡